Detalles de la búsqueda
1.
Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis.
Intest Res;
2024 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38835140
2.
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
J Crohns Colitis;
2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38877997
3.
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
J Crohns Colitis;
2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38878002
4.
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
Intest Res;
22(2): 172-185, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38720466
5.
Correction: Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
J Gastroenterol;
2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38814336
6.
A case of cytomegalovirus esophagitis difficult to distinguish from Crohn's disease exacerbation.
Clin J Gastroenterol;
2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38782847
7.
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus.
Dig Liver Dis;
2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38584033
8.
Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia?
Aliment Pharmacol Ther;
59(11): 1451-1452, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38643502
9.
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials.
Expert Rev Gastroenterol Hepatol;
18(1-3): 73-87, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38509826
10.
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights.
Aliment Pharmacol Ther;
59(8): 1005-1006, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38523122
11.
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Inflamm Bowel Dis;
2024 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459910
12.
White Blood Cell Counts and Future Relapse in Ulcerative Colitis under Low-Dose Thiopurine Treatment in Real-World Practice: A 3-Year Japanese Multi-Center Retrospective Cohort Study.
Inflamm Intest Dis;
9(1): 1-10, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38298887
13.
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
Eur J Gastroenterol Hepatol;
36(4): 404-415, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38417060
14.
Measurement of the intracellular active metabolites of thiopurine drugs to evaluate the enzymatic activity of nudix hydrolase 15 in human blood samples.
J Chromatogr B Analyt Technol Biomed Life Sci;
1234: 123993, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38246006
15.
Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety.
Aliment Pharmacol Ther;
59(4): 579-580, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38247151
16.
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
Inflamm Bowel Dis;
2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271613
17.
Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.
J Gastroenterol;
59(4): 302-314, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38277006
18.
Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol;
22(1): 22-33.e6, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37716619
19.
Immunomodulators after the discontinuation of anti-tumor necrosis factor-alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study.
J Gastroenterol Hepatol;
39(1): 66-73, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37823425
20.
Milan Ultrasound Criteria Predict Relapse of Ulcerative Colitis in Remission.
Inflamm Intest Dis;
8(3): 95-104, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38098495